Your browser doesn't support javascript.
loading
A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants.
Wu, Xuefan; Li, Wei; Rong, Heng; Pan, Jingdi; Zhang, Xiaowei; Hu, Qinxue; Shi, Zheng-Li; Zhang, Xian-En; Cui, Zongqiang.
Afiliación
  • Wu X; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.
  • Li W; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
  • Rong H; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.
  • Pan J; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.
  • Zhang X; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
  • Hu Q; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.
  • Shi ZL; University of Chinese Academy of Sciences, Beijing 100049, People's Republic of China.
  • Zhang XE; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.
  • Cui Z; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.
ACS Nano ; 18(27): 17749-17763, 2024 Jul 09.
Article en En | MEDLINE | ID: mdl-38935412
ABSTRACT
The rapid development of the SARS-CoV-2 vaccine has been used to prevent the spread of coronavirus 2019 (COVID-19). However, the ongoing and future pandemics caused by SARS-CoV-2 variants and mutations underscore the need for effective vaccines that provide broad-spectrum protection. Here, we developed a nanoparticle vaccine with broad protection against divergent SARS-CoV-2 variants. The corresponding conserved epitopes of the preexisting neutralizing (CePn) antibody were presented on a self-assembling Helicobacter pylori ferritin to generate the CePnF nanoparticle. Intranasal immunization of mice with CePnF nanoparticles induced robust humoral, cellular, and mucosal immune responses and a long-lasting immunity. The CePnF-induced antibodies exhibited cross-reactivity and neutralizing activity against different coronaviruses (CoVs). CePnF vaccination significantly inhibited the replication and pathology of SARS-CoV-2 Delta, WIV04, and Omicron strains in hACE2 transgenic mice and, thus, conferred broad protection against these SARS-CoV-2 variants. Our constructed nanovaccine targeting the conserved epitopes of the preexisting neutralizing antibodies can serve as a promising candidate for a universal SARS-CoV-2 vaccine.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nanopartículas / Anticuerpos Neutralizantes / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Epítopos Límite: Animals / Female / Humans Idioma: En Revista: ACS Nano Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nanopartículas / Anticuerpos Neutralizantes / Vacunas contra la COVID-19 / SARS-CoV-2 / COVID-19 / Epítopos Límite: Animals / Female / Humans Idioma: En Revista: ACS Nano Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos